Price
$23.04+4.68%Social Signal Score
Revenue
$17.03M+1646.59%Company Profile
- CEO
- Daniel R. Omstead
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.74
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 210.33
Financials
Revenue
$17.03M+1646.6%Net Income
$173.45M+86.0%EBITDA
$173.45M+0.0%Free Cash Flow
—EPS (diluted)
$3.17-3.9%Shares Outstanding (diluted)
54.79M+93.7%Operating Expenses
$0.00Cash & Debt
$59.00Return of Capital
$0.00Dividend per Share
$0.66Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $99.81M | $98.61M | $1.84 |
| 2024 | $10.77M | $184.95M | $3.55 |
| 2023 | $10.29M | $56.33M | $1.14 |
| 2022 | $8.27M | $-194.23M | $-4.10 |
| 2021 | $6.48M | $155.18M | $3.49 |
| 2020 | $8.93M | $241.20M | $5.50 |
| 2019 | $7.60M | $-145.29M | $-3.39 |
| 2018 | $6.78M | $69.20M | $1.64 |
| 2017 | $5.62M | $121.28M | $2.98 |
| 2016 | $4.80M | $-56.02M | $-1.44 |
| 2015 | $4.33M | $96.17M | $2.58 |
| 2014 | $2.14M | $222.02M | $6.20 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HQH's reported EPS growth of -10.5% a year over 11 years.
- EPS in 5 years
- $1.06
- Implied price
- $10.56
- Return from $20.95
- -12.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.25 — -74.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -20.5% | -30.1% | -25.9% | -22.5% | -19.7% | -17.2% |
| -15.5% | -25.7% | -21.3% | -17.7% | -14.6% | -11.9% |
| -10.5% | -21.3% | -16.6% | -12.8% | -9.6% | -6.7% |
| -5.5% | -16.9% | -12.0% | -7.9% | -4.5% | -1.5% |
| -0.5% | -12.5% | -7.3% | -3.1% | 0.5% | 3.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-13.04%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·18d ago·Neutral
HQH: Over 10% Yield On This Healthcare Fund HQH benefits from healthcare sector mean reversion after lagging the broader market for a decade. abrdn Healthcare Investors provides a lucrative 12% forward distribution yield backed by a managed distribution policy. HQH focuses primarily on small and mid cap biotech while incorporating select larger cap holdings.
View source ↗ - Newsseekingalpha.com·44d ago·Neutral
…de during bull markets. RVT's quarterly payout is tracking up from $0.31 to $0.33 in September, with additional regular and special year-end dividend upside in play. HQH's September payout is set to reach $0.66 per share – its highest single quarterly distribution since 2015 – with strong potential for a year-end special distribution.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy Abrdn Healthcare Investors is a concentrated, actively managed biotech-focused CEF trading at a 6.4% discount to NAV. I rate HQH a Buy: the fund delivered a 56% NAV return in twelve months, benefiting from an FDA regulatory shift and M&A tailwinds. The near-12% distribution is entirely funded by realized gains, not return of capital, distinguishing HQH from most high-payout CEFs.
View source ↗
Insider trading
Open-market buys and sells by HQH officers and directors.
- Bought
- $1.7m
- Sold
- —
40 trades
0 trades
- Mahai Chris Lavictoirebought
- Dimartino Rosebought
- Goetz Kathleenbought
- Reit Toddbought
- Maher Billbought
- Goodson Alan Rbought
- Omstead Daniel Rbought
- Omstead Daniel Rbought
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HQH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.